Zevia (ZVIA)
(Delayed Data from NYSE)
$1.05 USD
+0.03 (2.94%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $1.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Zevia (ZVIA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$2.45 | $5.00 | $0.90 | 140.20% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Zevia comes to $2.45. The forecasts range from a low of $0.90 to a high of $5.00. The average price target represents an increase of 140.2% from the last closing price of $1.02.
Analyst Price Targets (7 )
Broker Rating
Zevia currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.14 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, three are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ZVIA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/1/2024 | BMO Capital Markets | Andrew Strelzik | Strong Buy | Strong Buy |
5/9/2024 | Wells Fargo Securities | Christopher Carey | Hold | Hold |
5/9/2024 | Telsey Advisory Group | Dana Telsey | Hold | Hold |
5/1/2024 | Stephens | Jim Salera | Strong Buy | Strong Buy |
3/29/2024 | Goldman Sachs | Bonnie L Herzog | Hold | Hold |
2/28/2024 | Loop Capital Markets | Alton Stump | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.14 |
ABR (Last week) | 2.14 |
# of Recs in ABR | 7 |
Average Target Price | $2.45 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.11 |